Revenue rose 32% YoY and Ebitda surged 50% in Q1 FY27, but Systematix remains cautious on Lupin's near-term US business outlook amid increasing competition in key products.
Revenue rose 32% YoY and Ebitda surged 50% in Q1 FY27, but Systematix remains cautious on Lupin's near-term US business outlook amid increasing competition in key products.
<iframe src="https://hindustansphere.com/embed/cluster/4177562eb3701d30a131f432880706dfc77b60ea" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Lupin Q1 Review: Broad-Based Growth Impresses, But Systematix Sees US Competition Ahead — Check Target Price"></iframe>
